Roche CEO frustrated by Genentech talks

In an interview with the Wall Street Journal, Roche CEO Severin Schwan reiterated his confidence that Roche will complete its acquisition of Genentech, but expressed frustration with the so-far fruitless negotiations. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.